MicroBase Technology Valuation
Is 3184 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 3184 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 3184 (NT$11.8) wird unter unserer Schätzung des Fair Value (NT$45.3) gehandelt.
Deutlich unter dem Marktwert: 3184 wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3184?
Other financial metrics that can be useful for relative valuation.
What is 3184's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NT$1.04b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.9x |
Enterprise Value/EBITDA | 47.3x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 3184's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 50.2x | ||
6730 Lagis Enterprise | 28.9x | n/a | NT$1.3b |
4198 S&S Healthcare Holding | 11.9x | n/a | NT$1.2b |
4197 Visgeneer | 137.7x | n/a | NT$316.9m |
4161 Bioptik Technology Incorporation | 22.1x | n/a | NT$1.9b |
3184 MicroBase Technology | 43.4x | n/a | NT$1.0b |
Price-To-Earnings gegen Gleichaltrige: 3184 ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (42.4x) mit dem Durchschnitt der anderen Unternehmen (55.4x) vergleicht.
Price to Earnings Ratio vs Industry
How does 3184's PE Ratio compare vs other companies in the TW Medical Equipment Industry?
Price-To-Earnings gegen Industrie: 3184 ist teuer, wenn man sein Price-To-Earnings Verhältnis (39.7x) mit dem TW Medical Equipment Branchendurchschnitt (27x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is 3184's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 43.4x |
Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von 3184 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.